Shares of Quidel Corporation (NASDAQ: QDEL), jumped more than 6% after it announced that it has received 510(k) clearance from the United States Food and Drug Administration for the sale of its QuickVue RSV 10, a lateral flow immunoassay test for the qualitative detection of acute respiratory syncytial virus infections. Almost all infants will suffer from an RSV infection before the age of two. According to the United States Centers for Disease Control and Prevention, RSV is the most common cause of bronchiolitis and pneumonia in children under one year of age in the United States resulting in between 75,000 and 125,000 children hospitalized annually because of an RSV infection.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced early wednesday that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus. These data, presented previously at the BIT Life Science's 2nd Annual Summit of Antivirals held in Beijing, China in July 2009, documented for the first time safety and tolerability of inhaled ALN-RSV01 in a naturally infected patient population. The results also demonstrated statistically significant improvements in clinical symptom scores and reductions in the incidence of bronchiolitis obliterans syndrome, an irreversible and life-threatening complication of RSV infection in lung transplant patients resulting in approximately 50% mortality within three to five years of onset.
Shares of Green Mountain Coffee Roasters (NASDAQ: GMCR) plunged more than 13% in pre-market trading, a day after the coffee maker disclosed in a regulatory filing that the Securities and Exchange Commission is launching a probe into revenue recognition practices.
Full Disclosure: None
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced early wednesday that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus. These data, presented previously at the BIT Life Science's 2nd Annual Summit of Antivirals held in Beijing, China in July 2009, documented for the first time safety and tolerability of inhaled ALN-RSV01 in a naturally infected patient population. The results also demonstrated statistically significant improvements in clinical symptom scores and reductions in the incidence of bronchiolitis obliterans syndrome, an irreversible and life-threatening complication of RSV infection in lung transplant patients resulting in approximately 50% mortality within three to five years of onset.
Shares of Green Mountain Coffee Roasters (NASDAQ: GMCR) plunged more than 13% in pre-market trading, a day after the coffee maker disclosed in a regulatory filing that the Securities and Exchange Commission is launching a probe into revenue recognition practices.
Full Disclosure: None
